Diquafosol

Drug Profile

Diquafosol

Alternative Names: DE-089; Diquafosol sodium; Diquafosol tetrasodium; Diquas; Diquas ophthalmic solution 3%; INS 365; INS 365 Ophthalmic; INS 365 Respiratory; KPY 998; Prolacria

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inspire Pharmaceuticals
  • Developer Inspire Pharmaceuticals; Santen Pharmaceutical
  • Class Expectorants; Eye disorder therapies; Polyphosphates; Small molecules; Uracil nucleotides
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • Discontinued Bronchitis; Chronic obstructive pulmonary disease; Corneal ulcer; Cystic fibrosis

Most Recent Events

  • 19 Mar 2018 Santen Pharmaceutical completes a clinical trial for Dry eyes in Japan (Ophthalmic) (UMIN000024064)
  • 16 Mar 2018 Santen Pharmaceutical completes a clinical trial for Dry eyes in Japan (Ophthalmic) (UMIN000024041)
  • 01 Nov 2017 Registered for Dry eyes in China (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top